[go: up one dir, main page]

CO5770094A1 - Composicion farmaceutica orodispersable para la administracion aoromucosa o sublingual de agomelatina - Google Patents

Composicion farmaceutica orodispersable para la administracion aoromucosa o sublingual de agomelatina

Info

Publication number
CO5770094A1
CO5770094A1 CO06125383A CO06125383A CO5770094A1 CO 5770094 A1 CO5770094 A1 CO 5770094A1 CO 06125383 A CO06125383 A CO 06125383A CO 06125383 A CO06125383 A CO 06125383A CO 5770094 A1 CO5770094 A1 CO 5770094A1
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
composition according
orodispersible
core
diluent
Prior art date
Application number
CO06125383A
Other languages
English (en)
Inventor
Marc Julien
Francois Tharrault
Jean-Manuel Pean
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36663148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5770094(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CO5770094A1 publication Critical patent/CO5770094A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • A61K9/2826Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

? Composición farmacéutica de agomelatina orodispersable sólida recubierta, caracterizada por estar compuesta por: - un núcleo central o una capa central compuesta por agomelatina y excipientes que permiten la obtención de una formulación orodispersable; - un recubrimiento orodispersable. Composición farmacéutica conforme con la reivindicación 1, caracterizada por que la agomelatina se obtiene en forma cristalina II. Composición farmacéutica conforme con la reivindicación 1, caracterizada por que contiene un núcleo central. Composición farmacéutica conforme con la reivindicación 1, caracterizada por que contiene una capa central. Composición farmacéutica conforme con la reivindicación 1, caracterizada por que el núcleo o la capa central comprende un diluyente que imparte una propiedad orodispersable. Composición farmacéutica conforme con la reivindicación 5, caracterizada por que el diluyente utilizado en el núcleo central está basado en gránulos obtenidos por medio de coatomización de lactosa y almidón. Composición farmacéutica conforme con la reivindicación 1, caracterizada por que el núcleo o la capa central comprende un diluyente y un agente desintegrador. Composición farmacéutica conforme con la reivindicación 1, caracterizada por que el recubrimiento orodispersable comprende un diluyente que imparte una propiedad orodispersable.<EMI FILE="06125383_1" ID="1" IMF=JPEG HE=50 WI=50 >
CO06125383A 2005-12-14 2006-12-14 Composicion farmaceutica orodispersable para la administracion aoromucosa o sublingual de agomelatina CO5770094A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0512647A FR2894475B1 (fr) 2005-12-14 2005-12-14 Composition pharmaceutique orodispersible pour administra- -tion oromucosale ou sublinguale d'agomelatine

Publications (1)

Publication Number Publication Date
CO5770094A1 true CO5770094A1 (es) 2007-06-29

Family

ID=36663148

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06125383A CO5770094A1 (es) 2005-12-14 2006-12-14 Composicion farmaceutica orodispersable para la administracion aoromucosa o sublingual de agomelatina

Country Status (40)

Country Link
US (1) US7892575B2 (es)
EP (1) EP1800669B1 (es)
JP (2) JP4996225B2 (es)
KR (3) KR20070063420A (es)
CN (2) CN101919800A (es)
AP (1) AP2714A (es)
AR (1) AR058332A1 (es)
AT (1) ATE474561T1 (es)
AU (1) AU2006252051B2 (es)
BR (1) BRPI0605214A (es)
CA (1) CA2571202C (es)
CO (1) CO5770094A1 (es)
CR (1) CR8788A (es)
CU (1) CU23603B7 (es)
CY (1) CY1110824T1 (es)
DE (1) DE602006015592D1 (es)
DK (1) DK1800669T3 (es)
EA (1) EA013751B1 (es)
ES (1) ES2348994T3 (es)
FR (1) FR2894475B1 (es)
GE (1) GEP20084509B (es)
GT (1) GT200600500A (es)
HN (1) HN2008000874A (es)
HR (1) HRP20100517T1 (es)
IL (1) IL180036A0 (es)
MA (1) MA28722B1 (es)
MX (1) MXPA06014605A (es)
MY (1) MY143221A (es)
NO (1) NO20065701L (es)
NZ (1) NZ552025A (es)
PE (1) PE20071030A1 (es)
PL (1) PL1800669T3 (es)
PT (1) PT1800669E (es)
RS (1) RS51452B (es)
SG (1) SG133531A1 (es)
SI (1) SI1800669T1 (es)
TW (1) TWI327911B (es)
UA (1) UA86622C2 (es)
WO (1) WO2007068829A1 (es)
ZA (1) ZA200610511B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008801A2 (en) * 2006-07-11 2008-01-17 Mcneil Nutritionals, Llc Solid oral dosage vitamin and mineral compositions
SI2238974T1 (sl) 2009-04-09 2013-09-30 E-Pharma Trento S.P.A. Granulat za formuliranje orodisperzibilnih tablet
CN101781226B (zh) * 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
WO2011111027A2 (en) 2010-03-11 2011-09-15 Dexcel Pharma Technologies Ltd. Oral dispersible delayed release tablet formulation
CN101836966A (zh) * 2010-05-27 2010-09-22 北京万全阳光医药科技有限公司 一种含有阿戈美拉汀的口腔崩解片
CN101991559B (zh) * 2010-11-25 2012-04-18 天津市汉康医药生物技术有限公司 一种稳定的阿戈美拉汀胶囊药物组合物
US8426461B2 (en) 2011-01-17 2013-04-23 Takeda Pharmaceutical Company Limited Orally dispersible tablet
KR20140014134A (ko) 2011-01-17 2014-02-05 다케다 야쿠힌 고교 가부시키가이샤 구강내 분산정
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2765985A1 (en) 2011-10-14 2014-08-20 Takeda Pharmaceutical Company Limited Orally dispersible tablet
CN103169669B (zh) * 2011-12-26 2015-06-17 中国人民解放军军事医学科学院毒物药物研究所 阿戈美拉汀包衣微丸以及可在口中分散的药物组合物
CN102552211B (zh) * 2012-02-16 2013-07-17 福建广生堂药业股份有限公司 一种阿戈美拉汀的制剂组合物及其制备方法
FR3000896B1 (fr) * 2013-01-14 2016-08-26 Philippe Perovitch Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil
FR3001894A1 (fr) * 2013-02-08 2014-08-15 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
HUE036989T2 (hu) * 2013-06-06 2018-08-28 Zentiva Ks Agomelatin készítmény, amely agomelatint ko-kristály formájában tartalmaz
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
CN105007904A (zh) * 2014-02-07 2015-10-28 科学实验室药物公司 全天然无毒舌下药物递送系统
CN104523639B (zh) * 2014-12-11 2017-03-22 扬子江药业集团四川海蓉药业有限公司 一种阿戈美拉汀片剂及其制备方法
MX2022007331A (es) * 2019-12-20 2022-07-27 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transmucosal que contiene agomelatina.
CN113597303B (zh) * 2019-12-20 2022-11-18 罗曼治疗系统股份公司 含有阿戈美拉汀的经粘膜治疗系统
NL2031331B1 (en) 2022-03-18 2023-09-29 Plethora Therapeutics B V Transmucosal delivery of a short-acting psychedelic compound
NL2031332B1 (en) 2022-03-18 2023-09-29 Plethora Therapeutics B V Transmucosal delivery of psychoactive compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5762963A (en) * 1995-06-07 1998-06-09 Emory University Method and compositions for controlling oral and pharyngeal pain using capsaicinoids
ATE371439T1 (de) * 2000-07-27 2007-09-15 Roquette Freres Granulat bestehend aus stärke und laktose
JP2002338500A (ja) * 2001-03-15 2002-11-27 Yamanouchi Pharmaceut Co Ltd 苦味を低減した口腔内速崩壊錠および苦み低減化方法
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
FR2857263B1 (fr) * 2003-07-09 2005-09-09 Sanofi Synthelabo Nouvelle composition pharmaceutique solide comprenant de l'amisulpride
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine

Also Published As

Publication number Publication date
UA86622C2 (ru) 2009-05-12
AU2006252051A1 (en) 2007-06-28
US20070134331A1 (en) 2007-06-14
CU23603B7 (es) 2010-12-08
MY143221A (en) 2011-03-31
GT200600500A (es) 2007-07-25
PE20071030A1 (es) 2007-11-17
TW200738230A (en) 2007-10-16
NZ552025A (en) 2008-12-24
EP1800669A1 (fr) 2007-06-27
CA2571202A1 (fr) 2007-06-14
CY1110824T1 (el) 2015-06-10
MXPA06014605A (es) 2009-02-11
BRPI0605214A (pt) 2007-10-09
US7892575B2 (en) 2011-02-22
JP2012092132A (ja) 2012-05-17
AP2006003844A0 (en) 2006-12-31
ATE474561T1 (de) 2010-08-15
AP2714A (en) 2013-07-31
KR20070063420A (ko) 2007-06-19
CR8788A (es) 2008-08-21
IL180036A0 (en) 2008-01-20
AU2006252051B2 (en) 2013-03-14
SG133531A1 (en) 2007-07-30
FR2894475A1 (fr) 2007-06-15
EP1800669B1 (fr) 2010-07-21
SI1800669T1 (sl) 2010-11-30
JP4996225B2 (ja) 2012-08-08
TWI327911B (en) 2010-08-01
WO2007068829A1 (fr) 2007-06-21
ZA200610511B (en) 2008-05-28
KR20100012858A (ko) 2010-02-08
EA013751B1 (ru) 2010-06-30
MA28722B1 (fr) 2007-07-02
FR2894475B1 (fr) 2008-05-16
HRP20100517T1 (hr) 2010-10-31
KR20080108068A (ko) 2008-12-11
CA2571202C (fr) 2012-01-10
PL1800669T3 (pl) 2010-12-31
ES2348994T3 (es) 2010-12-21
AR058332A1 (es) 2008-01-30
KR101013667B1 (ko) 2011-02-10
RS51452B (sr) 2011-04-30
CN1981752B (zh) 2011-11-02
DK1800669T3 (da) 2010-10-25
NO20065701L (no) 2007-06-15
PT1800669E (pt) 2010-08-17
EA200602104A1 (ru) 2007-06-29
HK1101802A1 (en) 2007-10-26
JP2007182440A (ja) 2007-07-19
CU20060243A7 (es) 2009-09-08
DE602006015592D1 (de) 2010-09-02
CN1981752A (zh) 2007-06-20
CN101919800A (zh) 2010-12-22
HN2008000874A (es) 2012-02-27
GEP20084509B (en) 2008-10-10

Similar Documents

Publication Publication Date Title
CO5770094A1 (es) Composicion farmaceutica orodispersable para la administracion aoromucosa o sublingual de agomelatina
ES2524556T3 (es) Composiciones farmacéuticas
ATE407998T1 (de) Reinigungsmittel
JP2004515500A5 (es)
AR109263A2 (es) Composición que comprende moxidectina
JP2004532810A5 (es)
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
WO2009046425A3 (en) Micro- and nano-patterned surface features to reduce implant fouling and regulate wound healing
CL2009001936A1 (es) Compuestos derivados de piridazina, inhibidores de 11beta-hsd1; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de la diabetes, obesidad, dislipidemia, trastornos de ingestion de comida e hipertension (divisional de solicitud 1720-2006).
NO20051986D0 (no) Sammenhengende frigivelsesavlevering av amfetaminsalter.
GT200100152A (es) Nueva composicion farmaceutica para el tratamiento de la obesidad.
CY1112738T1 (el) Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη
EP1411904A4 (en) PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE
CL2004001372A1 (es) Alendronato monosodico en forma amorfa; proceso de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la resorcion osea en el tratamiento de fracturas, osteoporosis, osteoartritis, enfermedad de paget, osteohalisteresis, os
MX2007006343A (es) Forma farmaceutica multiparticulada que comprende ingredientes activos de acido nucleico mucoadhesivamente formulado y un proceso para producir la forma farmaceutica.
CL2004000652A1 (es) Uso de lactulosa para la inhibicion de infecciones por rotavirus de celulas animales o humanas.
BRPI0509194A (pt) formulação e método de comprimido revestido
DE60140997D1 (de) Therapeutische zusammensetzungen zur pulmonalen verabreichung
CY1107230T1 (el) Υποκατεστημενες ενωσεις 1-φαιναιθυλοπιπεριδινης, οι οποιες μεταξυ αλλων χρησιμοποιουνται σαν αναλγητικα
JP2004505922A5 (es)
GT200500191A (es) Derivados de pirido - pirimidina, su preparacion, su aplicacion en terapeutica
ATE363511T1 (de) Trennfilme
BRPI0415088A (pt) artigo e método
FR2886850B1 (fr) Composition a base d&#39;une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee

Legal Events

Date Code Title Description
FG Application granted